Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107.

Mol Oncol · 2026 · PMC13042512 · PMID 41216708

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

may be significantno p-value reported

This finding and the difference between the two PARPi may be significant considering the poor results of clinical trials with PARPi including Cisplatin‐pretreated patients.

also in 13,097 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.